by Robin Dvorak | Jun 30, 2025
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The company is developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of...
by Robin Dvorak | Jun 12, 2025
Genetix Biotherapeutics Inc. is a privately held, commercial-stage biotechnology company dedicated to delivering genetic therapies for patients with severe rare diseases. Backed by more than 30 years of pioneering genetic therapy innovation, the company has...
by Robin Dvorak | May 15, 2025
Altimmune is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapeutics for liver and cardiometabolic diseases. The Company’s lead program is pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of MASH,...
